geneOmbio Technologies Private Limited, VEDANT, S. No. 39/3, H. No. 1043, Yogi Park, Off Mumbai Bangalore Expressway, Baner, Pune 411045.Maharashtra. INDIA Tel: 020-27227040. Cell No. +91-9766363481, email: info@geneombiotechnologies.com, web[:www.geneombiotechnologies.com](http://www.geneombiotechnologies.com/)

HIV-1 Integrase Inhibitor Resistance Interpretation Report

|  |  |  |  |
| --- | --- | --- | --- |
|  **PATIENT DETAILS:** **Name of the patient** | : XXX | **Reporting Date/Time** | : 27.04.2022; 15:45 |
| **Age** | : 24 YEARS | **Gender** | : MALE |
| **Referred by** | : DR ALOK VASHISHTHA | **Lab Code** | : WIP001 |

#  TEST SAMPLE DETAILS:

|  |  |
| --- | --- |
| **Type of clinical sample** | : EDTA PLASMA |
| **Sample received Date/Time** | : 11-04-2022; 12:15 |
| **Assay Code** | : **gDRI (GBL-87)** |

**Report**

#  Summary Data

Sequence includes IN: codons 1 - 288 [Subtype:](https://hivdb.stanford.edu/page/hiv-subtyper/) C (96.49%)

#  Technology

Reverse Transcription mediated Polymerase chain reaction and Automated DNA sequencing.

#  Drug Resistance Interpretation: IN

IN Major Resistance Mutations: None

IN Accessory Resistance Mutations: None

Other Mutations: K14R, V31I, K42Q, L101I, T112V, T124A, T125A, G134S, K136Q, V201I, L234I, S255Q, D278A, C280H, S283G

|  |
| --- |
|  **Integrase Strand Transfer Inhibitors**  |
| **bictegravir (BIC)** | Susceptible |
| **cabotegravir (CAB)** | Susceptible |
| **dolutegravir (DTG)** | Susceptible |
| **elvitegravir (EVG)** | Susceptible |
| **raltegravir (RAL)** | Susceptible |

#  IN comments

None

|  |
| --- |
| **Mutation scoring: IN** |
| **INSTI** | **BIC** | **CAB** | **DTG** | **EVG** | **RAL** |
| Total | 0 | 0 | 0 | 0 | 0 |

|  |
| --- |
| ***Disclaimers:*** *‡The report represents only the specimen received in laboratory. PCR is a sensitive method, inconclusive and indeterminate**results may be obtained due to presence of PCR inhibitory factors in the sample. Poor quality sample, delayed logistics and improper temperature conditions while sample transportation can affect the test results. Interpretation algorithm: HIVdb Stanford.* |
|  *This test has been developed at geneOmbio Technologies Pvt Ltd, Pune and its performance characteristics have been verified.*  |

-End of the report-



Dr Amol D Raut (M.Sc. Ph D) Dr Yashwant Chavan (M.Sc. Ph D)

The laboratory report must be interpreted in association with the clinical profile of the patient by the clinician.

 BARCODE: GBL90818

Page ***1*** of ***1***